title: F508del-CFTR rescue: a matter of cell stress response.
abstract: Cystic fibrosis (CF) is a common inherited fatal disease affecting 70,000 people worldwide, with a median predicted age of survival of approximately 38 years. The deletion of Phenylalanine in position 508 of the Cystic Fibrosis Transmembrane conductance Regulator (F508del-CFTR) is the most common mutation in CF patients: the deleted protein, not properly folded, is degraded. To date no commercial drugs are available. Low temperature, some osmolytes and conditions able to induce heat shock protein 70 (Hsp70) expression and heat shock cognate 70 (Hsc70) inhibition result in F508del-CFTR rescue, hence restoring its physiological function: this review sheds light on the correlation between these several evidences. Interestingly, all these approaches have a role in the cell stress response (CSR), a set of cell reactions to stress. In addition, unpredictably, F508del-CFTR rescue has to be considered in the frame of CSR: entities that induce - or are induced during - the CSR are, in general, also able to correct trafficking defect of CFTR. Specifically, the low temperature induces, by definition, a CSR; osmolytes, such as glycerol and trimethylamine N-oxide (TMAO), are products of the CSR; pharmacological correctors, such as Matrine and 4-phenylbutirric acid (4PBA), down-regulate the constitutive Hsc70 in favor of an up-regulation of the inducible chaperone Hsp70, another component of the CSR. The identification of a common mechanism of action for different types of correctors could drive the discovery of new active molecules in CF, overcoming methods clinically inapplicable, such as the low temperature.
authors: Pharmacy Department, University of Genoa, Viale Benedetto XV 3, Genoa, Italy. erikanieddu@libero.it
authors: Erika
authors: E
authors: Nieddu
authors: Benedetta
authors: B
authors: Pollarolo
authors: Luisa
authors: L
authors: Merello
authors: Silvia
authors: S
authors: Schenone
authors: Mauro
authors: M
authors: Mazzei
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D003080:Cold Temperature; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D059865:Endoplasmic Reticulum Stress / Q000187:drug effects / Q000235:genetics; D018840:HSP70 Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008958:Models, Molecular; D058990:Molecular Targeted Therapy; D010654:Phenylbutyrates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D054730:Protein Interaction Domains and Motifs; D021381:Protein Transport / Q000187:drug effects; D011807:Quinolizines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000093842:Matrines
chemical_list: D000470:Alkaloids; D018840:HSP70 Heat-Shock Proteins; D010654:Phenylbutyrates; D011807:Quinolizines; C093349:cystic fibrosis transmembrane conductance regulator delta F508; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C075773:4-phenylbutyric acid; D003474:Curcumin; D000093842:Matrines